IQM Quantum Computers Appoints Jan Goetz as Sole CEO to Lead Next Phase of Global Growth

ESPOO, Finland--(BUSINESS WIRE)--Jan 26, 2026--

IQM Quantum Computers, a global leader in full-stack superconducting quantum computers, today announced a transition from its Co-CEO structure to a single Chief Executive Officer model.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126737805/en/

Co-founder and current Co-CEO Dr Jan Goetz becomes sole CEO effective since January 1 st, following a resolution passed by the IQM board. In addition, Dr Søren Hein has been appointed Chief Operating Officer and Deputy CEO.

As part of the transition, Mikko Välimäki steps down from his commercial role following a successful tenure as Co-CEO. He will continue to support the company as an advisor until 31 March 2026 to ensure continuity and a smooth transition.

“Our dual CEO approach has served IQM well over the past two years, and I want to thank Mikko Välimäki for his significant contributions,” said Dr. Sierk Poetting, Chairman of IQM’s Board of Directors. “Moving to a single-CEO structure reflects the maturity of the organisation and positions IQM to deliver the next phase of sustainable global expansion and long-term growth.”

Since its founding in 2018, IQM has grown into a major global quantum computing brand. Over the past year, IQM sold and shipped more on-premises quantum computers than any of its competitors and completed the largest Series B funding round in quantum outside the US.

The new leadership structure supports IQM’s continued focus on scaling quantum computers for industrial and commercial use. “I am delighted to welcome Søren to his new role. We will continue to expand and strengthen our leadership team to prepare for the next phase of strong growth, in line with our technology roadmap and long-term vision,” said Goetz.

He added: “IQM is well positioned to meet the evolving needs of AI-driven organisations and high-performance computing centres. This new structure will help us accelerate progress towards fault-tolerant quantum computing and deliver greater value to our customers and partners.”

Commenting on his appointment, Søren Hein said: “IQM has built an incredible team and culture of innovation. As we scale globally, I look forward to strengthening our operations, accelerating quantum adoption, and supporting long-term commercial success.”

Editor’s note:

About Jan Goetz:

In 2018, Goetz spun out IQM from Aalto University and VTT Technical Research Center of Finland together with his co-Founders and raised over $600M of capital for the company since then.

He was on the Board of the European Innovation Council EIC where he now serves as an EIC ambassador, and he holds a Board seat in the European Quantum Industry Consortium QuIC. He is also and member of the German Federal Economic Senate, an EIC Scaling Club Council member, member of the Hall of Future, as well as a Digital Leader and Global Innovator at the World Economic Forum (WEF).

In 2024, WirtschaftsWoche Magazin selected him as one of 30 executives to shape Germany, in 2023, he was selected as Founder of the Year by Handelsblatt. In 2020, Capital magazine selected him as one of 40 under 40 in Germany and he received an entrepreneurship award from the KAUTE Foundation.

Goetz did his doctorate on superconducting quantum circuits at TU Munich and worked as a Marie-Curie Fellow in Helsinki at Aalto University, where he holds the title of docent.

About Søren Hein:

Søren brings over 30 years of experience as a technology executive and investor across Europe and North America. He previously led Deeptech investments at MIG Capital, which also led IQM’s seed round in 2019. In addition, Hein has co-founded and run a startup in electric motors and served as Chief Technology Officer of the Wireless Systems business unit at Infineon. He holds a Ph.D. in Electrical Engineering and Computer Science from UC Berkeley and an MBA from INSEAD.

About IQM Quantum Computers:

IQM is a global leader in superconducting quantum computers. IQM provides both on-premises full-stack quantum computers and a cloud platform to access its computers. IQM customers include the leading high-performance computing centers, research labs, universities, and enterprises that have full access to IQM's software and hardware. IQM has over 300 employees with headquarters in Finland and a global presence in France, Germany, Italy, Japan, Poland, Spain, Singapore, South Korea, and the United States.

From left to right: Jan Goetz (Co-founder & CEO) and Søren Hein (Chief Operating Officer and Deputy CEO)

CARLSBAD, Calif.--(BUSINESS WIRE)--Jun 15, 2026--

Today, Argonaut Manufacturing Services (“Argonaut”), a US-based sterile fill-finish CDMO, and Ensera, a CDMO with facilities in the US, and Europe and Asia, specializing in final assembly and secondary packaging for drug delivery systems, announce a new strategic partnership.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615887507/en/

The collaboration aligns aseptic fill-finish with device assembly and packaging services to simplify supply chains, reduce operational risk and accelerate production timelines.

Argonaut provides aseptic fill-finish of vials, syringes, and cartridges using Annex 1 compliant isolator filling lines, as well as analytical testing and stability studies. Ensera complements these capabilities with final assembly of drug delivery devices, labelling, secondary packaging, kitting, serialization, sterilization management and testing for vials and drug delivery devices.

Through the partnership, customers can benefit from a streamlined quotation process covering both organizations’ services before starting a project. Projects that contract Argonaut and Ensera will benefit from closely coordinated project management that supports aligned fill-finish and device assembly activities across all stages of development and manufacturing.

Argonaut has completed an audit of Ensera’s U.S. facility and approved Ensera as a critical supply chain partner. This demonstrates the companies’ commitment to aligning high quality standards for clinical and commercial programs.

By leveraging expertise within and improving coordination between manufacturing stages, the partnership addresses several growing challenges in the combination product landscape, supply chain fragmentation, constrained capacity for mid-market programs, and increasing pressure to accelerate timelines for specialty biologics and biosimilars.

Rick Hancock, CEO, Argonaut, commented:

“More than ever, our clients are focused on developing their products in conjunction with autoinjectors to improve accessibility for patients. While this is a commendable goal, it adds complexity to supply chains. This partnership with Ensera eases that burden for sponsors. Just as our clients are focused on improving the patient experience, Argonaut is focused on improving our clients' experience.”

Jason Anderson, CEO, Ensera, added:

“This partnership reflects a shared focus on supporting the needs of pharmaceutical companies developing complex combination products, particularly in low to mid-volume scenarios where flexibility and coordination are essential. By aligning our device assembly and packaging expertise with Argonaut’s fill-finish capabilities, we are making it easier for customers to navigate critical transition points, reduce risk, and maintain momentum as their products progress toward commercialization.”

Both companies will be attending the BIO International Convention in San Diego, where they will be available to discuss how the collaboration can support upcoming programs.

About Argonaut

Located in Carlsbad, CA, Argonaut is a fill-finish CDMO specializing in clinical to commercial aseptic manufacturing of vials, syringes, and cartridges. The company operates two isolator-based, fully automated filling lines compliant with Annex 1 and FDA standards and utilizes high-yield processes and 100% weight checks to significantly reduce line losses. Argonaut also provides onsite analytical support and stability studies.

Learn more at www.argonautms.com

About Ensera

Ensera is a global CDMO supporting pharmaceutical and medical device companies with device design, final assembly, labeling, and secondary packaging of injectable formats, including autoinjectors and pre-filled syringes.

Its flexible GMP cleanroom operations across Europe and the US are optimized for low-to-medium batch volumes, supported by integrated quality systems and cold chain infrastructure. An approved assembly partner for leading autoinjector platforms from SHL, Ypsomed and BD, Ensera combines device and pharmaceutical expertise to deliver efficient, compliant supply for combination products.

Learn more at www.ensera.com

Ensera and Argonaut Partner to Streamline Supply for Drug-Device Combination Products